Skip to main content
Premium Trial:

Request an Annual Quote

BioRad to Buy DiaMed for $390M

NEW YORK (GenomeWeb News) - Bio-Rad said today it plans to buy reagent and screening tool-maker DiaMed Holding for around 477 million Swiss francs ($390 million).
 
The companies signed a definitive agreement under which Bio-Rad would buy 77.7 percent of DiaMed’s outstanding shares, after which Bio-Rad plans to conduct a tender offer buy nearly 13 percent of the remaining outstanding shares. The remaining 9.6 percent of DiaMed’s shares are treasury shares.
 
Bio-Rad said DiaMed generates roughly $200 million in annual sales to hospitals, labs, and blood banks.
 
John Goetz, Bio-Rad’s vice president and group manager of clinical diagnostics, said in a statement that DiaMed’s portfolio of products is a good fit with Bio-Rad’s existing diagnostics business.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.